Overview

A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To obtain preliminary evidence of antiretroviral activity of 1592U89 when administered in combination with other specific NRTI agents in NRTI experienced patients and to assess the safety and tolerance of multiple oral doses of 1592U89 when administered in combination with specific marketed NRTIs.
Phase:
Phase 2
Details
Lead Sponsor:
Glaxo Wellcome
Treatments:
Abacavir
Reverse Transcriptase Inhibitors